Update COVID-19

The PMCPA is following government guidance regarding COVID-19, therefore staff are working from home until further notice. No meetings will take place in the offices but, where appropriate, may be held online or by phone. Staff continue to be contactable via email or phone. 

The PMCPA has cancelled the Seminars previously scheduled for March and April 2020 following government guidance around COVID-19. Seminars are scheduled to take place on 30 June and 23 September.

The ABPI has cancelled the examinations for medical representatives scheduled for 21 April 2020, following government guidance around COVID-19. For more information contact abpievents@abpi.org.uk. Anyone who needs to extend the time available to take the examination to avoid breaching the ABPI Code of Practice should apply for an extension on the PMCPA website. The form is available under the Training section.

The Prescription Medicines Code of Practice Authority Welcome

The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI.  It was established by the ABPI on 1 January 1993.

The Authority is responsible for the provision of advice, guidance and training on the Code as well as for the complaints procedure.  It is also responsible for arranging for conciliation between companies when requested to do so and for arranging for the scrutiny of advertising and meetings on a regular basis.


Code of Practice Seminars  

The PMCPA holds regular training seminars on the requirements of the Code of Practice.  They are designed to explain the requirements of the Code, and are open to all. The next is scheduled for 30 June 2020.

Our free online eLearning tool is currently being updated.

The link follows for more information about Training opportunities



  • COVID-19 Updates on PMCPA staffing, Seminars and Examination extensions.

    18 March 2020

    read more
  • All the companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Daiichi-Sankyo has been required to issue a corrective statement and Otsuka Europe and Otsuka UK were publicly reprimanded.


    27 July 2019

    read more